An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors

Clinical Colorectal Cancer

Volumn 8, Issue 1, 2009, Pages 29-37

  Stephenson, Joe J ^a   Gregory, Charles ^a   Burris, Howard ^b   Larson, Tim ^c   Verma, Udit ^d   Cohn, Allen ^e   Crawford, Jeffrey ^f   Cohen, Roger B ^g   Martin, Julie ^a   Lum, Peggy ^h   Yang, Xinqun ^h   Amado, Rafael G ^h  

^a Cancer Centers of the Carolinas   (United States)

^b Tennessee Oncology   (United States)

^c North Memorial Humphrey Cancer Center   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

^e Rocky Mountain Cancer Center   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h AMGEN INC   (United States)

Author keywords

Anti epidermal growth factor receptor; Cetuximab; Monoclonal antibody; Targeted therapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PANITUMUMAB;

ACNE; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; NAUSEA; OPEN STUDY; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PRURITUS; SOLID TUMOR; TREATMENT RESPONSE; VOMITING;

EID: 61349191606     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.005     Document Type: Article

References (17)

1. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10:505-10.
2. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991; 47:87-98.
3. Toffoli G, De Mattia E, Cecchin E, et al. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers 2007; 22:S24-39.
4. Vectibix® (panitumumab) Prescribing Information. Amgen Inc, Thousand Oaks CA, 2008.
5. Erbitux® (cetuximab) Prescribing Information. ImClone Systems Inc., Branchburg, NJ and Bristol-Myers Squibb Company, Princeton, NJ, 2007.
6. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:29-31.
7. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58:984-90.
8. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23.
9. Yang XD, Jia XC, Corvalan JRF, et al. Eradication of established tumors by a fully human monocloncal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999; 59:1236-43.
10. Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006; 29:1-9.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
12. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-15.
13. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64.
14. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008; 19:92-8.
15. Berlin J, Posey J, Tchekmedyian S, et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2007; 6:427-32.
16. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25:3644-8.
17. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110:980-8.